Promising treatment strategies for hairy cell leukemia: BRAF inhibitors & combinations

Jan-Paul Bohn, MD, PhD, The Medical University of Innsbruck, Innsbruck, Austria, comments on a promising treatment strategy for hairy cell leukemia (HCL), highlighting the role of BRAF inhibitors and options for combination therapies with these agents. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.